PA8478701A1 - 1-(4-arilpiperazin-1-il)-omega-[n-(alpha,omega-dicarboximido)]-alcanos util como bloqueadores alpha1-adrenoceptores uro-selectivos - Google Patents

1-(4-arilpiperazin-1-il)-omega-[n-(alpha,omega-dicarboximido)]-alcanos util como bloqueadores alpha1-adrenoceptores uro-selectivos

Info

Publication number
PA8478701A1
PA8478701A1 PA19998478701A PA8478701A PA8478701A1 PA 8478701 A1 PA8478701 A1 PA 8478701A1 PA 19998478701 A PA19998478701 A PA 19998478701A PA 8478701 A PA8478701 A PA 8478701A PA 8478701 A1 PA8478701 A1 PA 8478701A1
Authority
PA
Panama
Prior art keywords
omega
useful
selectivos
arilpiperazin
adrenoceptores
Prior art date
Application number
PA19998478701A
Other languages
English (en)
Inventor
Nitya Anand
Neelima Sinha
Sanjay Jain
Anita Mehta
Jang Bahadur Gupta
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN3260DE1997 external-priority patent/IN188376B/en
Priority claimed from IN3261DE1997 external-priority patent/IN188377B/en
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of PA8478701A1 publication Critical patent/PA8478701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE HA ENCONTRADO QUE LOS NUEVOS DERIVADOS DE PIPERIZINA SUSTITUIDOS EN UN NITRÓGENO POR UN SISTEMA AROMÁTICO Y EN OTRO NITRÓGENO POR (2,5-DIOXOPIRROLIDINA)-1-YL) ALCANES O (2,6-DIOXOPIPERIDINA-1-YL) ALCANES, EXHIBEN UNA ACTIVIDAD ADRENÉRGICA 1A . LOS COMPUESTOS SON ÚTILES PARA EL TRATAMIENTO DE CONDICIONES DE ENFERMEDAD, TALES COMO ENFERMEDAD VASCULAR PERIFÉRICA, FALLA CONGESTIVA DEL CORAZÓN , HIPERTENSIÓN Y ESPECIALMENTE PARA HIPERTROFIA PROSTÁTICA BENIGNA.
PA19998478701A 1997-11-13 1999-07-21 1-(4-arilpiperazin-1-il)-omega-[n-(alpha,omega-dicarboximido)]-alcanos util como bloqueadores alpha1-adrenoceptores uro-selectivos PA8478701A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3260DE1997 IN188376B (es) 1997-11-13 1997-11-13
IN3261DE1997 IN188377B (es) 1997-11-13 1997-11-13

Publications (1)

Publication Number Publication Date
PA8478701A1 true PA8478701A1 (es) 2000-05-24

Family

ID=26324720

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998478701A PA8478701A1 (es) 1997-11-13 1999-07-21 1-(4-arilpiperazin-1-il)-omega-[n-(alpha,omega-dicarboximido)]-alcanos util como bloqueadores alpha1-adrenoceptores uro-selectivos

Country Status (2)

Country Link
US (6) US6083950A (es)
PA (1) PA8478701A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
EP1339682A1 (en) 2000-11-30 2003-09-03 Ranbaxy Laboratories, Ltd. 1,4-disubstituted piperazine derivatives useful as uro-selective $g(a)1-adrenoceptor blockers
CA2466432A1 (en) * 2001-11-08 2003-05-15 Atrium Medical Corporation Intraluminal device with a coating containing a therapeutic agent
AU2002251409A1 (en) * 2002-04-08 2003-10-20 Ranbaxy Laboratories Limited Carboximide derivatives as useful uro-selective alpha-1a adrenoceptor blockers
JP2005527578A (ja) * 2002-04-08 2005-09-15 ランバクシー ラボラトリーズ リミテッド 有用な尿選択的α１Ａアドレナリン受容体遮断薬としてのα，ω−ジカルボキシイミド誘導体
AU2003259391A1 (en) * 2003-08-25 2005-03-10 Ranbaxy Laboratories Limited Metabolites of 1-{3-4`4-(2-methoxyphenyl) piperazin-1-yl!-propyl}-piperidine-2, 6-dione for use in the treatment of benign prostatic hyperplasia
WO2005021522A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Synthesis of 1-‘4-(2-methoxyphenyl) piperazin-1-yl !-3-(2,6-dioxopiperidin-1-yl) propane
WO2005021506A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Synthesis of 1-[4-(2-methoxyphenyl) piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl) propane
AU2003259394A1 (en) * 2003-08-28 2005-03-16 Ranbaxy Laboratories Limited Preparation of 1-(4-(2-methoxy-phenyl)-piperazin-1-yl)-3-(2,6-dioxopiperidin-1-yl) propane hydrochloride
AR047759A1 (es) * 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
WO2005113498A1 (en) * 2004-05-19 2005-12-01 Ranbaxy Laboratories Limited Adrenergic receptor antagonists
WO2005118591A1 (en) * 2004-05-31 2005-12-15 Ranbaxy Laboratories Limited Condensed piperidine compounds acting as adrenergic receptor antagonists useful in the treatment of prostatic hyperplasia and lower urinary symptoms
WO2005118537A2 (en) * 2004-05-31 2005-12-15 Ranbaxy Laboratories Limited Arylpiperazine derivatives as adrenergic receptor antagonists
WO2006013445A2 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Thiazolidinedione derivatives as alpha adrenergic receptor antagonists
WO2006036970A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Method of thickening a coating using a drug
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006036982A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
WO2006036969A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Formation of barrier layer
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006051399A1 (en) * 2004-11-11 2006-05-18 Ranbaxy Laboratories Limited Piperazine derivatives useful as adrenergic receptor antagonists
WO2006117760A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Adrenergic receptor antagonists
WO2007029078A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Succinimide and glutarimide derivatives as adrenergic receptor antagonists
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
AU2006304590A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US20060247249A1 (en) * 2005-11-16 2006-11-02 Mohammad Salman Carboximide derivatives as useful uro-selective alpha-1a adrenoceptor blockers
WO2008057328A2 (en) 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
CA2978182A1 (en) 2015-03-17 2016-09-22 Regeneron Pharmaceuticals, Inc. Amino acid acylation reagents and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2922788A (en) 1958-05-26 1960-01-26 Parke Davis & Co Phenylpiperazine compounds and process for producing the same
FR1381425A (fr) 1962-10-24 1964-12-14 Ampex Dispositif de couplage pour la transmission de signaux
US3637705A (en) 1968-10-01 1972-01-25 Abbott Lab N-3 4-dihalo phenyl piperazines
BE788280A (fr) * 1971-09-04 1973-02-28 Pfizer Nouvelles 1-(3-trifluoro-methyl-phenyl)-4-((amido cyclique)- alkyl) piperazines et composition pharmaceutique les contenant
DE2727469A1 (de) * 1977-06-18 1978-12-21 Hoechst Ag Neue hexahydropyrimidine, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
JPS57197265A (en) * 1981-05-29 1982-12-03 Eisai Co Ltd Carboxylic acid imide derivative, its preparation and medicament containing the same
US4452798A (en) * 1982-06-22 1984-06-05 Warner-Lambert Company 1-Substituted phenyl-4-alkyl hydantoin piperazine compounds as antihypertensive agents
US4524206A (en) * 1983-09-12 1985-06-18 Mead Johnson & Company 1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives
US4675403A (en) * 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
US5403847A (en) 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
US6015819A (en) 1992-11-13 2000-01-18 Synaptic Pharmaceutical Corporation Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
US5508306A (en) 1992-11-13 1996-04-16 Synaptic Pharmaceutical Corporation Aromatic amine derivatives
US5578611A (en) 1992-11-13 1996-11-26 Synaptic Pharmaceutical Corporation Use of α-1C specific compounds to treat benign prostatic hyperplasia
PT748800E (pt) * 1995-06-09 2001-10-30 Hoffmann La Roche Derivados de pirimidinadiona pirimidinatriona triazinadiona como antagonistas do receptor alfa-1-adrenergico
US5859014A (en) * 1995-06-09 1999-01-12 Syntex (U.S.A.) Inc. Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists
US6057350A (en) 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists

Also Published As

Publication number Publication date
US6090809A (en) 2000-07-18
US6420366B1 (en) 2002-07-16
US6083950A (en) 2000-07-04
US6410735B1 (en) 2002-06-25
US6420559B1 (en) 2002-07-16
US6812344B1 (en) 2004-11-02

Similar Documents

Publication Publication Date Title
PA8478701A1 (es) 1-(4-arilpiperazin-1-il)-omega-[n-(alpha,omega-dicarboximido)]-alcanos util como bloqueadores alpha1-adrenoceptores uro-selectivos
ES2195970T3 (es) L-ribavirina y usos de la misma.
ES2084702T3 (es) Imidazoles sustituidos utiles como inhibidores de la angiotensina ii.
ES2189330T3 (es) Derivados heterociclicos n6 de la adenosina sustituidos.
AR016289A1 (es) N, n', n''-tris(2,4-bis [1-hidrocarbiloxi-2,2,6,6-tetrametilpiperidin-4-il)alquilamino]-s-triazin-6-il)-3,3'-etilendiiminodipropilaminas, sus isomeros y derivados con enlaces de puente y las composiciones polimericas estabilizadas con ellas
FI930772A0 (fi) Hydroxiureaderivat som saenker glugosnivao i blodet
PA8496301A1 (es) Inhibidores de metaloproteasas.
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
NO995817D0 (no) Kinolin- og kinoksalin-forbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase
CU23210A3 (es) NUEVOS COMPUESTOS DE OXABISPIDINE uTIL EN EL TRATAMIENTO DE ARRITMIAS CARDIACAS
ECSP941096A (es) Procedimiento para la preparacion de un derivado indol
PA8503301A1 (es) Compuestos para el tratamiento de la isquemia
ES2172585T3 (es) Derivado de benzoimidazol.
UY24006A1 (es) Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol.
ES2172264T3 (es) Nuevos derivados del p-diamino-benceno adecuados para el teñido de fibras de queratina.
AR009145A1 (es) Compuetos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores y composiciones farmaceuticas que los comprenden
ES2189121T3 (es) Mezcla de estabilizantes para materiales organicos.
CO5241280A1 (es) Alkanes 1-(4-arilpiperazina-1 delta i), omega[in-(alfa.omega dicarboximidoq)] utiles a manera de bloqueadores alfa1- adrenoreceptores uro-selectivos
ES2057262T3 (es) Derivados del cromano.
ES2183328T3 (es) Derivados de ciclopentenona.
IT1285777B1 (it) Processo di biotrasformazione di composti colchicinoidi nei corrispondenti 3-glicosilderivati
BR0110490A (pt) Agentes de tingimento contendo derivados de n-heteroarilmetil-m-fenilenodiamina para fibras de queratina bem como novos derivados de n-heteroarilmetil-m-fenilenodiamina
MX9307047A (es) Compuestos de quinazolinas y bencimidazoles substituidos.
ATE342998T1 (de) Replikation -defektive baculoviren expressionssystem
EA200000522A1 (ru) 5-htагонисты